Dr. Jin Google Scholar Citations
2024
Martinez, Criseyda; Xiong, Yan; Bartkowski, Alison; Harada, Ibuki; Ren, Xiaoxiao; Byerly, Jessica; Port, Elisa; Jian Jin*; Irie, Hanna*. Science Direct , “A PROTAC degrader suppresses oncogenic functions of PTK6 inducing apoptosis of breast cancer cells”, 2024 Nov 11:S2451-9456(24)00443-4.
PMID: 39541980
Inuzuka, H; Qian, Chao; Qi,Y; Xiong, Y; Wang, C;Wang,Z; Zhang, D;Zhang, C; Jin, J*; Wei, W*; ACS Pharmacology & Translational Science , “Targeted Degradation of Receptor-Interacting Protein Kinase 1 to Modulate the Necroptosis Pathway”, https://doi.org/10.1021/acsptsci.4c00421
Corbin, J.; Yu, X.; Cai, L.; Jin, J.; Wang, G. G.* Oncogene , “EZH2 PROTACs target EZH2- and FOXM1-associated oncogenic nodes, suppressing breast cancer cell growth”, 2024, 43, 2722-2736. PMID:39112519
Nigam, A. K.; Hurley, M. F. D.; Lid, F.; Konkoľováe, E.; Klímae, M.; Trylčováe, J.; Pollice, R.; Çinaroǧluh, S. S.; Levin-Konigsbergb, R.; Handjayafg, J.; Schapiradi, M.; Chaud, R.; Perveen, S.; Ho-Leung Ng, H.; Kaniskan, Ü.; Hank, Y.; Singhl, S.; Gorgullamno, C.; Kundajeab, A.; Jin, J.; Voelz, V. A.; Webere, J.; Nenckae, R.; Bourae, E.; Vedadi, M.*; Aspuru-Guzik, A.* Digital Discovery, “Targeted Degradation of Receptor-Interacting Protein Kinase 1 to Modulate the Necroptosis Pathway”. 2024, 3, 1327-1341.https://doi.org/10.1021/acsptsci.4c00421
Xue Z; Qin L; Xuan H.; Luo K.; Huang M; Xie, L; Su, Y.; Xu L; Harsh, J.; Dale, B.; Shi, X.; Chen, X.; Kaniskan, HÜ.; Jin, J*., Wen, H.*, Science Advances, “A potent and selective ENL degrader suppresses oncogenic gene expression and leukemia progression.”. 2024 Aug 30;10(35).eado1432. PMID:39196923. PMCID: PMC11352836
Graboski, A.L.;Simpson,J.B.; Pellock;S.J.; Mehta, N.; Creekmore, B.C.; Ariyarathna; Y. ;Bhatt, A.P.; Jariwala,P.B.; Sekela, J.J.; Kowalewski, M.E.; Barker, N.K.; Mordant, A.L.; Borlandelli, V.B.; Overkleeft, H.; Herring, L.E.; Jin, J.; I James L, Redinbo,M.R.. RSC Chemical Biology Journal “Advanced piperazine-containing inhibitors target microbial β-glucuronidases linked to gut toxicity.” PMID: 39211470; PubMed Central PMCID: PMC11353122. RSC Chem Biol. 2024 Jul 16;5(9):853-865
Hu,X; Kabir, M; Lin, Y; Xiong Y; Parsons, R; Gu, W; Jin, J*. Journal of Medicinal Chemistry “Design, Synthesis, and Evaluation of p53Y220C Acetylation Targeting Chimeras (AceTACs)”, , August, 2024, 67, 14633−14648 PMID:39169826
Wang, S, E.; Xiong, Y.;Jang, M, A,; Park, K, S.; Donahue, M.; Velez J.; Jin J.*; Jiang, Y, H.*, Molecular Therapy, “Newly developed oral bioavailable EHMT2 inhibitor as a potential epigenetic therapy for Prader-Willi syndrome”, PMID: 38796700
Kabir, M.; Qin, L.; Luo, K.; Xiong, Y.; Sidi, R. A.; Park, K.-S.*; Jin, J.*, Discovery and characterization of a novel Cereblon-recruiting PRC1 bridged PROTAC degrader. Journal of Medicinal Chemistry. 2024, 67:6880-6892. PMID: 38607318.
Velez, J.; Han, Y.; Yim, H.; Yang, P.; Deng, Z.; Park, K.-s.; Kabir, M.; Kaniskan, H. Ü.; Xiong, Y.*; Jin, J.*, Discovery of the first-in-class G9a/GLP PROTAC degrader. Journal of Medicinal Chemistry. 2024, 67(8):6397-6409. PMID: 28602846.
Deng, Z; Chen, L; Qian, C; Liu,J; Wu,Q; Song,X; Xiong,Y.; Wang, Z; Hu, X; Inuzuka, H; Zhong, Y; Lin; Y; Pham, N.D.; Shi,Y; Wei ;W.*; Jin,J.* Angewandte Chemie International Edition “The First-in-class Deubiquitinase-targeting Chimera Stabilizes and Activates cGAS.”, 2024 Aug 16; e202415168. doi: 10.1002/anie.202415168. PubMed PMID: 39150898.
Kim, Y.; Gumpper, R. H.; Liu, Y; Kocak, D. D.; Xiong, Y.; Cao, C.; Deng, Z.; Krumm, B. E.; Jain, M. K.; Zhang, S.; Jin, J.; Roth, B. L., Nature “Bitter taste receptor activation by cholesterol and an intracellular tastant.” 2024, 628(8008):664-671. PMID: 38600377.
Liu, J; Hu, X.; Luo, K; Xiong, Y; Chen, L.; Wang, Z.; Inuzuka, H.; Qian, C.; Yu, X.; Xie, L.; Muneer, A.; Zhang, D.; Paulo, J. A.; Chen, X.; Jin, J.*; Wei, W.*, Journal of the American Chemical Society“, USP7-based deubiquitinase-targeting chimeras stabilize AMPK.” 2024, Apr 10; PMID: 38597345.
Xiong, Y.; Greschik, H.; Johansson, C.; Seifert, L.; Gamble, V.; Park, K.-s.; Fagan, V.; Li, F.; Chau, I.; Vedadi, M.; Arrowsmith, C. H.; Brennan, P.; Fedorov, O.; Jung, M.; Farnie, G.; Liu, J.; Oppermann, U. *; Schüle, R. *; Jin, J. *, Discovery of a potent, selective, and cell-active SPIN1 inhibitor. Journal of Medicinal Chemistry. 2024, 67(7):5837-5853. PMID: 38533580.
Nylund, P.; Garrido-Zabala, B.; Párraga, A. A.; Vasquez, L.; Pyl, P. T.; Harinck, G. M.; Ma, A.; Jin, J.; Öberg, F.; Kalushkova, A.; Wiklund, H. J.*, PVT1 interacts with polycomb repressive complex 2 to suppress genomic regions with pro-apoptotic and tumour suppressor functions in multiple myeloma. Haematologica, 2024, 109 (2): 567-577. PMID: 37496441.
Wang, Z.; Zhang, D.; Qiu, X.; Inuzuka, H.; Xiong, Y.; Liu, J.; Chen, L.; Chen, H.; Xie, L.; Kaniskan, H. Ü.; Chen, X.; Jin, J. *; Wei, W. *, Journal of the American Chemical Society . “Structurally specific Z-DNA proteolysis targeting chimera enables targeted degradation of adenosine deaminase acting on RNA”, 2024, 146 (11): 7584-7593. PMID: 38469801.
Velez, J.; Dale, B.; Park, K.-S.; Kaniskan, H. Ü.; Yu, X. *; Jin, J. *, “Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2”. European Journal of Medicinal Chemistry,. 2024, 267, 116154. PMID: 38602846.,
2023
Dang, F.; Bai, L.; Dong, J.; Hu, X.; Wang, J.; Paulo, J. A.; Xiong, Y.; Liang, X.; Sun, Y.; Chen, Y.; Guo, M.; Wang, X.; Huang, Z.; Inuzuka, H.; Chen, L.; Chu, C.; Liu, J.; Zhang, T.; Rezaeian, A.-H.; Liu, J.; Kaniskan, H. Ü.; Zhong, B.; Zhang, J.; Letko, M.; Jin, J. *; Lan, K. *; Wei, W. *, USP2 inhibition prevents infection with ACE2-dependent coronaviruses in vitro and is protective against SARS-CoV-2 in mice. Science Translational Medicine. 2023, 15 (725): eadh7668. PMID: 38055802.
Yu, X.; Li, D.; Kottur, J.; Kim, H. S.; Herring, L. E.; Yu, Y.; Xie, L.; Hu, X.; Chen, X.; Cai, L.; Liu, J.; Aggarwal, A. K.; Wang, G. G. *; Jin, J.*, Discovery of Potent and Selective WDR5 Proteolysis Targeting Chimeras as Potential Therapeutics for Pancreatic Cancer. Journal of Medicinal Chemistry. 2023, 66(23): 16168–16186. PMID: 38019706.
Umaña, J.D.; Wasserman S.R.; Song L; Goel A.A; Yu X.; Jin J; Hathaway N.A. *, Chemical Epigenetic Regulation of Adeno-Associated Virus Delivered Transgenes. Human Gene Therapy. 2023, 34(17-18): 947-957. PMID: 37624737.
Pogorelov, V. M.*; Martini, M. L.; Jin, J.; Wetsel, W. C.;* Caron, M. G., Dopamine-Depleted Dopamine Transporter Knockout (DDD) Mice: Dyskinesia with L-DOPA and Dopamine D1 Agonists. Biomolecules, 2023, 13(11): 1658. PMID: 38002340.
Muneer, A.;Wang, L.; Xie, L.; Zhang, F.; Wu, B.; Mei, L.; Lenarcic, E. M.; Feng, E. H.; Song, J.; Xiong, Y.; Yu, X.; Wang, C.; Jain, K.; Strahl, B.; Cook, J. G.; Wan, Y. Y.; Moorman, N. J.; Song, H.; Jin, J.; Chen, X. *, “Non-canonical function of histone methyltransferase G9a in the translational regulation of chronic inflammation.” Cell Chemical Biology, 2023, 30:1525-1541.e7. PMID: 37858336.
Gray, Z. H.;Chakraborty, D.; Duttweiler, R. R.; Alekbaeva, G. D.; Murphy, S. E.; Chetal, K.; Ji, F.; Ferman, B. I.; Honer, M. A.; Wang, Z.; Myers, C.; Sun, R.; Kaniskan, H. Ü.; Toma, M. M.; Bondarenko, E. A.; Santoro, J. N.; Miranda, C.; Dillingham, M. E.; Tang, R.; Gozani, O.; Jin, J.; Skorski, T.; Duy, C.; Lee, H.; Sadreyev, R. I.; Whetstine, J. R.*, Epigenetic balance ensures mechanistic control of MLL amplification and rearrangement. Cell, 2023, 186(21):4528-4545.e18. PMID: 37788669.
Wang Z.; Liu J.; Qiu X.; Zhang D.; Inuzuka H.; Chen L.; Chen H.; Xie L.; Kaniskan HÜ.; Chen X.; Jin J.* ; Wei W.* , Methylated Nucleotide-Based Proteolysis-Targeting Chimera Enables Targeted Degradation of Methyl-CpG-Binding Protein 2. Journal of the American Chemical Society . 2023, 145(40): 21871–21878. PMID: 37774414.
Salas-Estrada, L.; Provasi, D.; Qiu, X.; Kaniskan, H. Ü.; Huang, X. P.; DiBerto, J. F.; Lamim Ribeiro, J. M.; Jin, J.; Roth, B. L.; Filizola, M.; De Novo Design of κ-Opioid Receptor Antagonists Using a Generative Deep-Learning Framework. Journal of Chemical Information and Modeling, 63(16): 5056–5065. PMID: 37555591.
Rialdi, A.; Duffy, M.; Scopton, A. P.; Fonseca, F.; Zhao, J. N.; Schwarz, M.; Molina-Sanchez, P.; Mzoughi, S.; Arceci, E.; Abril-Fornaguera, J.; Meadows, A.; Ruiz de Galarreta, M.; Torre, D.; Reyes, K.; Lim, Y. T.; Rosemann, F.; Khan, Z. M.; Mohammed, K.; Wang, X.; Yu, X.; Jin, J.; Guccione, E; Dar, A. C.; WNTinib is a multi-kinase inhibitor with specificity against β-catenin mutant hepatocellular carcinoma. Nature cancer, 2023, 4(8):1157-1175. PMID: 37537299.
Gao, J.; Yang, L.; Lei, S.; Zhou, F.; Nie, H.; Peng, B.; Xu, T.; Chen, X.; Yang, X.; Sheng, C.; Rao, Y.; Pu, K.; Jin, J.; Xu, Z.; Yu, H.; Stimuli-activatable PROTACs for precise protein degradation and cancer therapy. Science bulletin, 2023, 68(10): 1069–1085. PMID: 37169612.
Kabir, M.; Sun, N.; Hu, X.; Martin, T. C.; Yi, J.; Zhong, Y.; Xiong, Y.; Kaniskan, H. Ü.; Gu, W.; Parsons, R.; Jin, J.*; Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53. Journal of the American Chemical Society 2023, 145(27):14932-14944. PMID: 37365684.
Velez, J.; Kaniskan, H. Ü.*; Jin, J.*; Recent advances in developing degraders & inhibitors of lysine methyltransferases. Current Opinion in Chemical Biology, 2023, 76:102356. PMID: 37379717.
Schwalm, M. P.; Krämer, A.; Dölle, A.; Weckesser, J.; Yu, X.; Jin, J.; Saxena, K.; Knapp, S.; Tracking the PROTAC degradation pathway in living cells highlights the importance of ternary complex measurement for PROTAC optimization. Cell Chemical Biology, 2023, 30:753-765.e8. PMID: 37354907.
Kabir, M.; Yu, X.; Kaniskan, H. Ü.*; Jin, J.*; Chemically induced degradation of epigenetic targets. Chemical Society Reviews, 2023, 52(13):4313-4342. PMID: 37314393.
Zhao, N.; Ho, J. S. Y.; Meng, F.; Zheng, S.; Kurland, A. P.; Tian, L.; Rea-Moreno, M.; Song, X.; Seo, J. S.; Kaniskan, H. Ü.; Te Velthuis, A. J. W.; Tortorella, D.; Chen, Y. W.; Johnson, J. R.; Jin, J.*; Marazzi, I.*; Generation of host-directed and virus-specific antivirals using targeted protein degradation promoted by small molecules and viral RNA mimics. Cell Host Microbe, 2023, 31(7):1154-1169.e10. PMID: 37339625.
Yi, J.; Li, H.; Chu, B.; Kon, N.; Hu, X.; Hu, J.; Xiong, Y.; Kaniskan, H. U.; Jin, J.; Gu, W*; Inhibition of USP7 induces p53-independent tumor growth suppression in triple-negative breast cancers by destabilizing FOXM1. Cell Death & Differentiation, 2023, 30(7):1799-1810. PMID: 37291217.
Singh, I.; Li, F.; Fink, E. A.; Chau, I.; Li, A.; Rodriguez-Hernández, A.; Glenn, I.; Zapatero-Belinchón, F. J.; Rodriguez, M. L.; Devkota, K.; Deng, Z.; White, K.; Wan, X.; Tolmachova, N. A.; Moroz, Y. S.; Kaniskan, H. Ü.; Ott, M.; García-Sastre, A.; Jin, J.; Fujimori, D. G.; Shoichet, B. K.*; Structure-Based Discovery of Inhibitors of the SARS-CoV-2 Nsp14 N7-Methyltransferase. J. Med. Chem, 2023, 66(12):7785-7803. PMID: 37294077.
Wang, Z.; Liu, J.; Chen, H.; Qiu, X.; Xie, L.; Kaniskan, H. Ü.; Chen, X.; Jin, J.*; Wei, W.*; Telomere Targeting Chimera Enables Targeted Destruction of Telomeric Repeat-Binding Factor Proteins. Journal of the American Chemical Society. 2023, 145(19):10872-10879. PMID: 37141574.
Qiang, N.; Ao, J.; Nakamura, M.*; Chiba, T.; Kusakabe, Y.; Kaneko, T.; Kurosugi, A.; Kogure, T.; Ma, Y.; Zhang, J.; Ogawa, K.; Kan, M.; Iwanaga, T.; Sakuma, T.; Kanayama, K.; Kanzaki, H.; Kojima, R.; Nakagawa, R.; Kondo, T.; Nakamoto, S.; … Jin, J.; Kato, N.; Alteration of the tumor microenvironment by pharmacological inhibition of EZH2 in hepatocellular carcinoma. Int immunopharmacol. 2023, 118:110068. PMID: 37001386.
Vital, T.; Wali, A.; Butler, K. V.; Xiong, Y.; Foster, J. P.; Marcel, S. S.; McFadden, A. W.; Nguyen, V. U.; Bailey, B. M.; Lamb, K. N.; James, L. I.; Frye, S. V.; Mosely, A. L.; Jin, J.; Pattenden, S. G.; Davis, I. J.*; MS0621, a novel small-molecule modulator of Ewing sarcoma chromatin accessibility, interacts with an RNA-associated macromolecular complex and influences RNA splicing. Frontiers in Oncology, 2023, 13:1099550. PMID: 36793594.
Yu, X.; Wang, J.; Gong, W.; Ma, A.; Shen, Y.; Zhang, C.; Liu, X.; Cai, L.; Liu, J.; Wang, G. G.*; Jin, J.*; Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader. Oncogene, 2023, 42(13):994-1009. PMID: 36747009.
Park, K. S.; Qin, L.; Kabir, M.; Luo, K.; Dale, B.; Zhong, Y.; Kim, A.; Wang, G. G.; Kaniskan, H. Ü.; Jin, J*; Targeted Degradation of PRC1 Components, BMI1 and RING1B, via a Novel Protein Complex Degrader Strategy. Advanced science (Weinheim, Baden-Württemberg, Germany). 2023, 10(10):e2205573. PMID: 36737841.
Sun, N.; Kabir, M.; Lee, Y.; Xie, L.; Hu, X.; Velez, J.; Chen, X.; Kaniskan, H. Ü.*; & Jin, J*; Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer. Journal of Medicinal Chemistry. 2023, 66(1):596-610. PMID: 36538511.
Marcellino, B. K.; Yang, X.; Ümit Kaniskan, H.; Brady, C.; Chen, H.; Chen, K.; Qiu, X.; Clementelli, C.; Herschbein, L.; Li, Z.; Elghaity-Beckley, S.; Arandela, J.; Kelly, B.; Hoffman, R.; Liu, J.; Xiong, Y.; Jin, J.*; Shih, A. H.*; An MDM2 degrader for treatment of acute leukemias. Leukemia, 2023, 37(2):370-378. PMID: 36309559
2022
Jin, J.*; Dar, A. C.; Doroshow, D. “Advancing Cancer Precision Medicine by Creating a Better Toolbox for Cancer Therapy” in The Frontiers of Medical Research: Cancer (Science/AAAS, Washington, DC, 2022), pp. 10-12.
Xiong, Y.; Zhong, Y.; Yim, H.; Yang, X.; Park, K. S.; Xie, L.; Poulikakos, P. I.; Han, X.; Xiong, Y.; Chen, X.; Liu, J.; Jin, J.*; Bridged Proteolysis Targeting Chimera (PROTAC) Enables Degradation of Undruggable Targets. Journal of the American Chemical Society. 2022, 144(49):22622-22632. PMID: 36448571.
Wang, J.; Park, K. S.; Yu, X.; Gong, W.; Earp, H. S.; Wang, G. G.*; Jin, J.; * Cai, L.*; A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation. Nucleic acids research, 2022, 50(19):10929-10946. PMID: 36300627.
Yu, X.; Xu, J.; Cahuzac, K. M.; Xie, L.; Shen, Y.; Chen, X.; Liu, J.*; Parsons, R. E.*; Jin, J*; Novel Allosteric Inhibitor-Derived AKT Proteolysis Targeting Chimeras (PROTACs) Enable Potent and Selective AKT Degradation in KRAS/BRAF Mutant Cells. Journal of Medicinal Chemistry, 2022, 65(20):14237-14260. PMID: 36197750.
Kurimchak, A. M.; Herrera-Montávez, C.; Montserrat-Sangrà, S.; Araiza-Olivera, D.; Hu, J.; Neumann-Domer, R.; Kuruvilla, M.; Bellacosa, A.; Testa, J. R.; Jin, J.; Duncan, J. S.*; The drug efflux pump MDR1 promotes intrinsic and acquired resistance to PROTACs in cancer cells. Science signaling, 2022, 15(749), eabn2707. PMID: 36041010.
Cai, W. L.; Chen, J. F.; Chen, H.; Wingrove, E.; Kurley, S. J.; Chan, L. H.; Zhang, M.; Arnal-Estape, A.; Zhao, M.; Balabaki, A.; Li, W.; Yu, X.; Krop, E. D.; Dou, Y.; Liu, Y.; Jin, J.; Westbrook, T. F.; Nguyen, D. X.; Yan, Q.; Human WDR5 promotes breast cancer growth and metastasis via KMT2-independent translation regulation. Elife, 2022, 11, e78163. PMID: 36043466.
Klima, M.; Khalili Yazdi, A.; Li, F.; Chau, I.; Hajian, T.; Bolotokova, A.; Kaniskan, H. Ü.; Han, Y.; Wang, K.; Li, D.; Luo, M.; Jin, J.; Boura, E.; Vedadi, M. Crystal structure of SARS-CoV-2 nsp10-nsp16 in complex with small molecule inhibitors, SS148 and WZ16. Protein Science. 2022, 31(9). PMID: 36040262.
Zhang, S.; Chen, H.; Zhang, C.; Yang, Y.; Popov, P.; Liu, J.; Krumm, B. E.; Cao, C.; Kim, K.; Xiong, Y.; Katritch, V.; Shoichet, B. K.; Jin, J.; Fay, J. F.*; Roth, B. L.*; Inactive and active state structures template selective tools for the human 5-HT5A receptor. Nature Structural & Molecular Biology. 2022, 29(7), 677-687. PMID: 35835867.
Meng, F.; Xu, C.; Park, K. S.; Kaniskan, H. U.*; Wang, G. G.* Jin, J.*; Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos. Journal of Medicinal Chemistry. 2022, 65(15), 10611-10625. PMID: 35895319.
Montanaro, A.; Kitara, S.; Cerretani, E.; Marchesini. M.; Rompietti, C.; Pagliaro, L.; Gherli, A.; Su, A.; Minchillo, M. L.; Caputi, M.; Fioretzaki, R.; Lorusso, B.; Ross, L.; Alexe, G.; Masselli, E.; Marozzi, M.; Rizzi, F. M. A.; La Starza, R.; Mecucci, C.; Xiong, Y.; Jin, J.; Falco, A.; Knoechel, B.; Aversa, F.; Candini, O.; Quaini, F.; Sportoletti, P.; Stegmaier, K.; Roti, G.*; Identification of an Epi-metabolic dependency on EHMT2/G9a in T-cell acute lymphoblastic leukemia. Cell Death & Disease. 2022, 13(6), 551. PMID: 35710782
Park, K. S.; Xiong, Y.*; Yim, H.; Velez, J.; Babault, N.; Kumar, P.; Liu, J.; Jin, J.*; Discovery of the First-in-Class G9a/GLP Covalent Inhibitors. Journal of Medicinal Chemistry. 2022, 65(15), 10506-10522. PMID: 35763668.
Liu, J.; Yu, X.; Chen, H.; Kaniskan H. Ü.; Xie, L.; Chen, X.; Jin, J*.; Wei, W*.; TF-DUBTACs Stabilize Tumor Suppressor Transcription Factors. Journal of the American Chemical Society. 2022, 144(28), 12934-12941. PMID: 35786952.
Dale, B.; Anderson, C.; Park, K. S.; Kaniskan H. U.; Ma, A.; Shen Y.; Zhang, C.; Xie, L.; Chen, X.; Yu, X.*; Jin, J.*; Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2. ACS Pharmacol. Transl. Sci. 2022, 5, 7, 491–507. PMID: 358337138.
Yu, X.; Cheng, M.; Lu, K.; Shen, Y.; Zhong, Y.; Liu, J.; Xiong, Y.; Jin, J.*; Exploring Degradation of Mutant and Wild-Type Epidermal Growth Factor Receptors Induced by Proteolysis-Targeting Chimeras. J. Med. Chem. 2022, 65(12), 8416-8443. PMID: 35675209.
Wu, Q.; Nie, D. Y.; Ba-Alawi, W.; Ji, Y.; Zhang, Z.; Cruickshank, J.; Haight J.; Ciamponi F. E.; Chen, J.; Duan, S.; Shen, Y.; Liu, J.; Marhon, S. A..; Mehdipour, P.; Szewczyk, M. M.; Dogan-Artun, N.; Chen, W.; Zhang, L. X.; Deblois, G.; Prinos, P.; Massirer, K. B.; Barsyte-Lovejoy, D.; Jin, J.; De Carvalho, D. D.; Haibe-Kains, B.; Wang, X.; Cescon, D. W.; Lupien, M.*.; Arrowsmith, C .H.*. PRMT inhibition induces a viral mimicry response in triple-negative breast cancer. Nat. Chem. Biol. 2022, 18(8), 821-830. PMID: 35578032.
Li, D.; Yu, X.; Kottur, J.; Gong, W.; Zhang, Z.; Storey, A. J.; Tsai, Y. H.; Uryu, H.; Shen, Y.; Byrum, S. D.; Edmondson, R. D.; Mackintosh, S. G.; Cai, L.; Liu, Z.; Aggarwal, A. K.; Tackett, A. J.; Liu, J.; Jin, J.*; Wang, G. G.* Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic. Oncogene. 2022, 41(24), 3328-3340. PMID: 35525905.
Xu, C.; Meng, F.; Park, K. S.; Storey, A. J.; Gong, W.; Tsai, Y. H.; Gibson, E.; Byrum, S. D.; Li, D.; Edmondson, R. D.; Mackintosh, S. G.; Vedadi, M.; Cai, L.; Tackett, A. J.; Kaniskan, H. U.; Jin, J.*; Wang, G. G.* A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. Cell Chem. Biol. 2022, 29, 386-397.e9. PMID: 34469831.
Ren, Z.; Kim, A.; Huang, Y. T.; Pi, W. C.; Gong, W.; Yu, X.; Qi, J.; Jin, J.; Cai, L.; Roeder, R. G.; Chen, W. Y.; Wang, G. G*; A PRC2-Kdm5b axis sustains tumorigenicity of acute myeloid leukemia. Proc. Natl. Acad. Sci. U S A 2022, 119, e2122940119. PMID: 35217626
Wang, J.; Yu, X.; Gong, W.; Liu, X.; Park, K.-S.; Ma, A.; Tsai, Y.-H.; Shen, Y.; Onikubo, T.; Pi, W.-C.; Allison, D. F.; Liu, J.; Chen, W.-Y.; Cai, L.; Roeder, R. G.; Jin, J.*; Wang, G. G.* EZH2 noncanonically binds cMyc and p300 through a cryptic transactivation domain to mediate gene activation and promote oncogenesis. Nature Cell Biology 2022, 24, 384-399. PMID: 35210568
Esposito, D.; Pant, I.; Shen, Y.; Qiao, R. F.; Yang, X.; Bai, Y.; Jin, J.; Poulikakos, P. I.; Aaronson, S. A. ROCK1 mechano-signaling dependency of human malignancies driven by TEAD/YAP activation. Nat Commun 2022, 13, 703. PMID: 35121738.
Yu, X.; Xu, J.; Shen, Y.; Cahuzac, K.; Park, K.; Dale, B.; Liu, J.*; Parsons, R.*; Jin, J.* Discovery of potent, selective, and in vivo efficacious AKT kinase protein degraders via structure-activity relationship studies. J. Med. Chem. 2022, 65, 3644-3666. PMID: 35119851
Cao Tao, Martini Michael L., Park Kwang-Su, Kaniskan H. Ümit and Jin Jian, Pyrimidines and Their Benzo Derivatives. In: Black, David StC, Cossy, Janine and Stevens, Christian V. Eds., Comprehensive Heterocyclic Chemistry IV, Elsevier, 2022, 86-228.
2021
Yu, X.; Xu, J.; Xie, L.; Wang, L.; Shen, Y.; Cahuzac, K.; Chen, X.; Liu, J.*; Parsons, R.*; Jin, J.* Design, Synthesis and Evaluation of Potent, Selective and Bioavailable AKT Kinase Degraders. J. Med. Chem. 2021, 64, 18054-18081. PMID: 34855399.
Yang, X.; Wang, X.; Li, Z.; Duan, S.; Li, H.; Jin, J.; Zhang, Z.; Gu, W., An unexpected role for Dicer as a reader of the unacetylated DNA binding domain of p53 in transcriptional regulation. Sci. Adv. 2021, 7, eabi6684. PMID: 34705508, PMCID: PMC8550248.
Kusakabe, Y.; Chiba, T.; Oshima, M.; Koide, S.; Rizq, O.; Aoyama, K.; Ao, J.; Kaneko, T.; Kanzaki, H.; Kanayama, K.; Maeda, T.; Saito, T.; Nakagawa, R.; Kobayashi, K.; Kiyono, S.; Nakamura, M.; Ogasawara, S.; Suzuki, E.; Nakamoto, S.; Yasui, S.; Mikata, R.; Muroyama, R.; Kanda, T.; Maruyama, H.; Kato, J.; Mimura, N.; Ma, A.; Jin, J.; Zen, Y.; Otsuka, M.; Kaneda, A.; Iwama, A.; Kato, N., EZH1/2 inhibition augments the anti-tumor effects of sorafenib in hepatocellular carcinoma. Sci. Rep. 2021, 11, 21396. PMID: 34725436, PMCID: PMC8560765.
Herviou, L.; Ovejero, S.; Izard, F.; Karmous-Gadacha, O.; Gourzones, C.; Bellanger, C.; De Smedt, E.; Ma, A.; Vincent, L.; Cartron, G.; Jin, J.; De Bruyne, E.; Grimaud, C.; Julien, E.; Moreaux, J., Targeting the methyltransferase SETD8 impairs tumor cell survival and overcomes drug resistance independently of p53 status in multiple myeloma. Clinical Epigenetics 2021, 13, 174. PMID:34530900, PMCID: PMC8447659.
Liu, L.; Dattaroy, D.; Simpson, K. F.; Barella, L. F.; Cui, Y.; Xiong, Y.; Jin, J.; Konig, G. M.; Kostenis, E.; Roman, J. C.; Kaestner, K. H.; Doliba, N. M.; Wess, J., Gq signaling in alpha cells is critical for maintaining euglycemia. JCI Insight , 2021 , e152852